Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Drs. Hope Rugo, Alison Conlin, Marleen Kok and Heather McArthur discuss results of recent pivotal clinical trials and their impact on current and evolving treatment paradigms for patients with metastatic triple-negative breast cancer.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Apply actionable biomarkers alongside tumor and patient-specific factors to guide treatment decisions in early and advanced triple-negative breast cancer (TNBC)
• Develop personalized treatment strategies informed by current and emerging trial evidence for early and advanced TNBC

Acknowledgment of Educational Grant Support

This activity is supported by educational grants from AstraZeneca; BioNTech; Daiichi Sankyo, Inc; and Merck Sharp & Dohme Corp.

Chair:

Hope S. Rugo, MD

Director, Women’s Cancers Program
Division Chief, Breast Medical Oncology
Professor, Department of Medical Oncology & Therapeutics Research
City of Hope Comprehensive Cancer Center
Duarte, CA
Professor Emeritus, UCSF
San Francisco, CA

Disclosures: Advisor: Ambryx, Chugai, OBI Pharma, Puma; Consultant: Ambryx, Chugai, Mylan, Napo, OBI Pharma, Puma, Sanofi; Researcher: AstraZeneca, Daiichi Sankyo, F. Hoffman-La Roche AG/Genentech, Gilead Sciences, Lilly, Merck & Co, Novartis Pharmaceuticals Corporation, Pfizer, Stemline Therapeutics

Faculty:

Alison K. Conlin, MD

Medical Oncologist
Providence Cancer Institute
Portland, OR

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Daiichi Sankyo, Genentech, Gilead, Stemline

Marleen Kok, MD, PhD

Group Leader, Breast Cancer Immunotherapy Group
The Netherlands Cancer Institute
Amsterdam, The Netherlands

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: AstraZeneca, BMS, Daiichi, Gilead, MSD, Roche; Grant/Research Funding: AstraZeneca, BMS, Daiichi, Roche; Non-financial Support: Natera

Heather McArthur, MD, MPH

Professor of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, TX

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: ALX, AstraZeneca, Celcuity, Daiichi-Sankyo, Genentech, Gilead, Lilly, Merck, Novartis, Pfizer, Stemline; Grant/Research Funding: Bristol-Myers Squibb, BTG, MedImmune LLC/AstraZeneca, Merck (to institution)

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on the treatment of early-stage triple-negative breast cancer, go to https://www.gotoper.com/sabcs25tnbc-enduring.

Release Date

January 30, 2026

Expiration Date

January 30, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.